Navitoclax (ABT-263)

For research use only. Not for use in humans.

目录号：S1001

CAS No. 923564-51-6

Navitoclax (ABT-263)是一种有效的Bcl-xL，Bcl-2和Bcl-w抑制剂，无细胞试验中K_i分别为≤0.5 nM，≤1 nM和≤1 nM，但与Mcl-1和A1结合微弱。Phase 2。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 3285.53	现货
5mg	RMB 975.71	现货
10mg	RMB 1631.61	现货
25mg	RMB 3016.58	现货
100mg	RMB 7950.36	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Navitoclax (ABT-263)发表文献201篇：

Cell, 2019, 178(2):302-315.e23

PubMed: 31299200 ( click the link to review the publication )

Cell, 2019, 178(2):361-373

PubMed: 31204100 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Cell, 2019, 36(1):68-83

PubMed: 31257073 ( click the link to review the publication )

Cell Metab, 2019, 30(1):129-142

PubMed: 31155496 ( click the link to review the publication )

Cancer Discov, 2018, 8(12):1598-1613

PubMed: 30254092 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(2):112-117

PubMed: 29200207 ( click the link to review the publication )

Cancer Cell, 2017, 32(4):490-505.e10

PubMed: 29017059 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(3):407-414.e4

PubMed: 28017795 ( click the link to review the publication )

Nature, 2016, 538(7626):477-482

PubMed: 27760111 ( click the link to review the publication )

Nat Med, 2016, 22(3):262-9

PubMed: 26828195 ( click the link to review the publication )

Nat Cell Biol, 2020, 4

PubMed: 32367049 ( click the link to review the publication )

Sci Transl Med, 2020, 15;12(539) pii: eaax3799

PubMed: 32295900 ( click the link to review the publication )

Cell Res, 2020, 27;1-16

PubMed: 32341413 ( click the link to review the publication )

Mol Cell, 2020, 7;S1097-2765(20)30269-0

PubMed: 32416067 ( click the link to review the publication )

Nat Commun, 2020, 11(1):752

PubMed: 32029722 ( click the link to review the publication )

Nat Commun, 2020, 11(1):259

PubMed: 31937780 ( click the link to review the publication )

Mol Syst Biol, 2020, 16(2):e8664

PubMed: 32073727 ( click the link to review the publication )

Blood Cancer J, 2020, 10(6):72

PubMed: 32591499 ( click the link to review the publication )

Aging Cell, 2020, 19(4):e13133

PubMed: 32175667 ( click the link to review the publication )

Elife, 2020, 2;9:e54954

PubMed: 32484436 ( click the link to review the publication )

Eur J Cancer, 2020, 126:93-103

PubMed: 31927215 ( click the link to review the publication )
Cancers (Basel), 2020, 12(9)E2551

PubMed: 32911681 ( click the link to review the publication )

Cancers (Basel), 2020, 10;12(2) pii: E406

PubMed: 32050632 ( click the link to review the publication )

Cell Death Dis, 2020, 8;11(6):443

PubMed: 32513939 ( click the link to review the publication )

Aging (Albany NY), 2020, 7;12(9):8221-8240

PubMed: 32379705 ( click the link to review the publication )

PLoS Negl Trop Dis, 2020, 14(3):e0008150

PubMed: 32196500 ( click the link to review the publication )

Sci Rep, 2020, 14;10(1):222

PubMed: 31937836 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 4;526(3):612-617

PubMed: 32247610 ( click the link to review the publication )

Laryngoscope, 2020, 10.1002

PubMed: 31894587 ( click the link to review the publication )

Platelets, 2020, 10.1080/09537104.2020.1724276

PubMed: 32079453 ( click the link to review the publication )

Biomater Sci, 2020, 8(8):2264-2273

PubMed: 32134074 ( click the link to review the publication )

PLoS One, 2020, 15(7):e0234103

PubMed: 32645016 ( click the link to review the publication )

Leuk Lymphoma, 2020, 1-5

PubMed: 32627634 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):537-548

PubMed: 31911540 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(14):14174-14188

PubMed: 32692721 ( click the link to review the publication )

J Hematol Oncol, 2020, 13(1):95

PubMed: 32677976 ( click the link to review the publication )

NPJ Breast Cancer, 2020, 6:30

PubMed: 32715085 ( click the link to review the publication )

Cancers (Basel), 2020, 12(8):E2137

PubMed: 32752193 ( click the link to review the publication )

Cancers (Basel), 2020, 12(8):E2298

PubMed: 32824203 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2020, 15;106(4):867-877

PubMed: 31786278 ( click the link to review the publication )

Cell Rep, 2020, 32(2):107897

PubMed: 32668248 ( click the link to review the publication )

Cell Rep, 2020, 31(13):107830

PubMed: 32610131 ( click the link to review the publication )

Free Radic Biol Med, 2020, 152:227-234

PubMed: 32217194 ( click the link to review the publication )

FASEB J, 2020, 10.1096/fj.201900218R

PubMed: 32619061 ( click the link to review the publication )

Mol Cell, 2019, 74(1):19-31

PubMed: 30878284 ( click the link to review the publication )
Nat Chem Biol, 2019, 15(3):232-240

PubMed: 30692684 ( click the link to review the publication )

Sci Adv, 2019, 5(7):eaau9433

PubMed: 31392262 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0713

PubMed: 31409615 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(10):e10769

PubMed: 31468706 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0775

PubMed: 31806643 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1398

PubMed: 31492749 ( click the link to review the publication )

Thyroid, 2019, 29(4):540-548

PubMed: 30869573 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 30860026 ( click the link to review the publication )

Oncogene, 2019, 38(1):47-59

PubMed: 30076411 ( click the link to review the publication )

Br J Pharmacol, 2019, 10.1111/bph.14773

PubMed: 31222722 ( click the link to review the publication )

J Med Chem, 2019, 62(15):6913-6924

PubMed: 31339316 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12841

PubMed: 31663663 ( click the link to review the publication )

Cell Death Dis, 2019, 10(5):342

PubMed: 31019203 ( click the link to review the publication )

FASEB J, 2019, 10.1096/fj.201900815RR

PubMed: 31408372 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.04.011

PubMed: 31155509 ( click the link to review the publication )

Stem Cell Res Ther, 2019, 10(1):86

PubMed: 30867061 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(23)

PubMed: 31801186 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5912

PubMed: 30976015 ( click the link to review the publication )

J Biol Chem, 2019, 294(3):875-886

PubMed: 30482844 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:218

PubMed: 31462891 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:222

PubMed: 31467488 ( click the link to review the publication )

Prostate, 2019, 79(11):1347-1359

PubMed: 31228231 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):1251

PubMed: 31881855 ( click the link to review the publication )

BMC Cancer, 2019, 20(1):1

PubMed: 31892356 ( click the link to review the publication )
Cell Biosci, 2019, 9:60

PubMed: 31367332 ( click the link to review the publication )

Transl Oncol, 2019, 12(4):683-692

PubMed: 30844579 ( click the link to review the publication )

Photodiagnosis Photodyn Ther, 2019, 10.1016/j.pdpdt.2019.08.016

PubMed: 31430575 ( click the link to review the publication )

Cancer Biomark, 2019, 24(1):51-59

PubMed: 30614795 ( click the link to review the publication )

Nat Metab, 2019, 1(11):1074-1088

PubMed: 31799499 ( click the link to review the publication )

Cell Oncol (Dordr), 2019, 42(3):287-301

PubMed: 30859392 ( click the link to review the publication )

Immunity, 2018, 48(4):675-687

PubMed: 29653696 ( click the link to review the publication )

J Allergy Clin Immunol, 2018, 142(5):1647-1650.e3

PubMed: 30048671 ( click the link to review the publication )

Nat Commun, 2018, 9(1):215

PubMed: 29335437 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(19):10195-10215

PubMed: 30239926 ( click the link to review the publication )

Neuro Oncol, 2018, 20(2):203-214

PubMed: 29016820 ( click the link to review the publication )

Cell Death Discov, 2018, 4:107

PubMed: 30479840 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )

Cell Death Dis, 2018, 9(7):713

PubMed: 29915306 ( click the link to review the publication )

Cell Death Dis, 2018, 92(10)

PubMed: 23640461 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):21

PubMed: 29343814 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):907

PubMed: 30185782 ( click the link to review the publication )

Stem Cell Res Ther, 2018, 9(1):108

PubMed: 29669575 ( click the link to review the publication )

Antioxidants (Basel), 2018, 10.3390/antiox7110150

PubMed: 30373097 ( click the link to review the publication )

Biochemical Pharmacology, 2018, 10.1016/j.bcp.2018.01.031

PubMed: ( click the link to review the publication )

Mar Drugs, 2018, 16(12)

PubMed: 30572618 ( click the link to review the publication )

Biomed Pharmacother, 2018, 107:139-145

PubMed: 30086460 ( click the link to review the publication )

Cell Cycle, 2018, 17(17):2175-2186

PubMed: 30198376 ( click the link to review the publication )

Toxicol In Vitro, 2018, 46:229-236

PubMed: 28947240 ( click the link to review the publication )
Oncotarget, 2018, 9(28):20075-20088

PubMed: 29732004 ( click the link to review the publication )

Oncotarget, 2018, 9(24):16701-16717

PubMed: 29682179 ( click the link to review the publication )

J Exp Med, 2018, 215(1):319-336

PubMed: 29263218 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(10):1226-1236

PubMed: 28945232 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(9):1116-1129

PubMed: 28846096 ( click the link to review the publication )

J Clin Invest, 2017, 127(2):635-650

PubMed: 28094768 ( click the link to review the publication )

Nat Commun, 2017, 8:16078

PubMed: 28714472 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1940

PubMed: 29208897 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1067

PubMed: 29057925 ( click the link to review the publication )

Cancer Res, 2017, 77(8):2018-2028

PubMed: 28202526 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3513-3526

PubMed: 28522750 ( click the link to review the publication )

Cancer Res, 2017, 77(9):2476-2487

PubMed: 28209615 ( click the link to review the publication )

Cancer Res, 2017, 77(9):2512-2521

PubMed: 28202514 ( click the link to review the publication )

Cell Death Dis, 2017, 8(10):e3062

PubMed: 28981092 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2563-2571

PubMed: 28839001 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2178-2190

PubMed: 28611106 ( click the link to review the publication )

Cell Commun Signal, 2017, 15(1):16

PubMed: 28464919 ( click the link to review the publication )

Cell Discov, 2017, 3:16048

PubMed: 28101374 ( click the link to review the publication )

Dis Model Mech, 2017, 10(9):1109-1115

PubMed: 28883017 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(12):1632-1641

PubMed: 28713162 ( click the link to review the publication )

Int J Oncol, 2017, 10.3892/ijo.2017.3914

PubMed: 28350129 ( click the link to review the publication )

Biomed Pharmacother, 2017, 95:1574-1579

PubMed: 28950657 ( click the link to review the publication )

Anticancer Drugs, 2017, 28(10):1141-1149

PubMed: 28885267 ( click the link to review the publication )

Oncotarget, 2017, 8(18):29558-29573

PubMed: 28418907 ( click the link to review the publication )
Oncotarget, 2017, 8(49):86312-86324

PubMed: 29156797 ( click the link to review the publication )

Oncotarget, 2017, 8(34):57047-57057

PubMed: 28915653 ( click the link to review the publication )

Viruses, 2017, 9(10)

PubMed: 28946654 ( click the link to review the publication )

Nat Microbiol, 2016, 1:15034

PubMed: 27572165 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Autophagy, 2016, 12(7):1083-93

PubMed: 27172402 ( click the link to review the publication )

Clin Cancer Res, 2016, pii: clincanres.2827.2015

PubMed: 27126996 ( click the link to review the publication )

Leukemia, 2016, 30(2):351-60

PubMed: 26488112 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(6):1624-9

PubMed: 26811457 ( click the link to review the publication )

Cancer Res, 2016, 76(23):7001-7011

PubMed: 27671680 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

Int J Cancer, 2016, 138(2):507-14

PubMed: 26260669 ( click the link to review the publication )

Anal Chem, 2016, 88(16):8050-7

PubMed: 27425825 ( click the link to review the publication )

Endocr Relat Cancer, 2016, 23(1):35-45

PubMed: 26483423 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(11):2915-2926

PubMed: 27913811 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(1):27-35

PubMed: 26575826 ( click the link to review the publication )

Cell Cycle, 2016, 15(3):394-402

PubMed: 26694174 ( click the link to review the publication )

PLoS One, 2016, 11(10):e0164250

PubMed: 27723829 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(4):1792-7

PubMed: 27613092 ( click the link to review the publication )

J Biomol Screen, 2016, 21(7):680-8

PubMed: 27245141 ( click the link to review the publication )

Mol Med Rep, 2016, 13(1):403-11

PubMed: 26548896 ( click the link to review the publication )

Data Brief, 2016, 6:710-4

PubMed: 26958630 ( click the link to review the publication )

Oncotarget, 2016, 7(1):845-59

PubMed: 26625317 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27153554 ( click the link to review the publication )
Cell Death Differ, 2015, 10.1038/cdd.2015.73

PubMed: 26045046 ( click the link to review the publication )

Breast Cancer Res, 2015, 17:26

PubMed: 25848915 ( click the link to review the publication )

Breast Cancer Res, 2015, 17(1):533

PubMed: 25778369 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(1):298-306

PubMed: 25344583 ( click the link to review the publication )

Frontiers in Oncology, 2015, 4:368

PubMed: 25566506 ( click the link to review the publication )

Sci Rep, 2015, 5:14739

PubMed: 26446703 ( click the link to review the publication )

Ann Surg Oncol, 2015, 22(9):3079-86

PubMed: 25524010 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0120913

PubMed: 25811469 ( click the link to review the publication )

PLoS One, 2015, 10(1):e0116998

PubMed: 25615615 ( click the link to review the publication )

Microvasc Res, 2015, 101:72-81

PubMed: 26122935 ( click the link to review the publication )

Oncol Lett, 2015, 10(2):829-834

PubMed: 26622578 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26008975 ( click the link to review the publication )

Oncotarget, 2015, 6(29):27388-402

PubMed: 26317541 ( click the link to review the publication )

Oncotarget, 2015, 6(25):21557-71

PubMed: 26188358 ( click the link to review the publication )

Oncotarget, 2015, 6(17):15551-65

PubMed: 26036632 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26059440 ( click the link to review the publication )

Oncotarget, 2015, 6(34):36456-71

PubMed: 26474387 ( click the link to review the publication )

Sci Rep, 2015, 5:16406

PubMed: 26553339 ( click the link to review the publication )

J Clin Invest, 2014, 124(1):117-28

PubMed: 24292713 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):4737-52

PubMed: 25250573 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(41):14788-93

PubMed: 25267614 ( click the link to review the publication )

Chem Sci, 2014, 5, 2794–2803

PubMed: ( click the link to review the publication )

Int J Cancer, 2014, 136(3):688-98

PubMed: 24895203 ( click the link to review the publication )
Oncogene, 2014, 10.1038/onc.2014.21

PubMed: 24608435 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1291

PubMed: 24922075 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02798-13

PubMed: 24752266 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574 ( click the link to review the publication )

Skelet Muscle, 2014, 4(1):4

PubMed: 24484587 ( click the link to review the publication )

PLoS One, 2014, 9(10):e108371

PubMed: 25289887 ( click the link to review the publication )

PLoS One, 2014, ;9(6):e99404

PubMed: 24901320 ( click the link to review the publication )

Blood, 2013, 121(10):1850-7

PubMed: 23303820 ( click the link to review the publication )

Blood, 2013, 122(9):1587-98

PubMed: 23881917 ( click the link to review the publication )

Cell Death Differ, 2013, 20(11):1475-84

PubMed: 23832116 ( click the link to review the publication )

Haematologica, 2013,

PubMed: 23850807 ( click the link to review the publication )

Int J Cancer, 2013, 132(4):978-87

PubMed: 22821746 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e883

PubMed: 24157877 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e742

PubMed: 23887633 ( click the link to review the publication )

Neoplasia, 2013, 15(5):568-78

PubMed: 23633928 ( click the link to review the publication )

Cell Cycle, 2013, 12(18):2960-8

PubMed: 23974105 ( click the link to review the publication )

PLoS One, 2013, 8(5):e64051

PubMed: 23691145 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 434(3):695-700

PubMed: 23602897 ( click the link to review the publication )

Exp Dermatol, 2013, 22(8):518-23

PubMed: 23802633 ( click the link to review the publication )

Helsinki Metropolia University, 2013, Jens Desloovere

PubMed: ( click the link to review the publication )

Cancer Res, 2012, 72(12):2949-56

PubMed: 22505651 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Cancer Lett, 2012, 339(2):288-97

PubMed: 23200668 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e351

PubMed: 22825469 ( click the link to review the publication )
Toxicol Sci, 2012, 128(1):79-91

PubMed: 22491427 ( click the link to review the publication )

J Biol Chem, 2012, 287(34):28598-608

PubMed: 22733819 ( click the link to review the publication )

Mol Biol Cell, 2012, 23(12):2240-52

PubMed: 22535522 ( click the link to review the publication )

Transfusion, 2012, 52(10):2094-103

PubMed: 22320126 ( click the link to review the publication )

Blood, 2011, 117(26):7145-54

PubMed: 21562047 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(12):3956-68

PubMed: 21652541 ( click the link to review the publication )

PLoS One, 2011, 6(9):e24590

PubMed: 21931768 ( click the link to review the publication )

Biochem Biophys Res Commun, 2011, 408(2):344-9

PubMed: 21514278 ( click the link to review the publication )

Clin Cancer Res, 2010, 16(16):4217-25

PubMed: 20601444 ( click the link to review the publication )

产品安全说明书

Bcl-2抑制剂选择性比较

生物活性

产品描述

Navitoclax (ABT-263)是一种有效的Bcl-xL，Bcl-2和Bcl-w抑制剂，无细胞试验中K_i分别为≤0.5 nM，≤1 nM和≤1 nM，但与Mcl-1和A1结合微弱。Phase 2。

靶点

Bcl-xL ^[1] (Cell-free assay)	Bcl-2 ^[1] (Cell-free assay)	Bcl-w ^[1] (Cell-free assay)
<=0.5 nM(Ki)	<=1 nM(Ki)	<=1 nM(Ki)

体外研究

ABT-263有效抑制Bcl-2蛋白家族，用荧光偏振分析法测试ABT-263作用于Bcl-xL, Bcl-2和 Bcl-w时，K_i分别为0.5, 1和1 nM。^[1]ABT-263结构上与ABT-737相关。ABT-263阻断Bcl-2 和Bcl-XL与凋亡前体蛋白相互作用。Bcl-2家族成员Bcl-2,Bcl-XL, 和Mcl-1的过量表达通常都与肿瘤的修复及抗药性有关。ABT-263作用于过量表达的Bcl-2 和Bcl-XL时显示出保护作用，EC50分别为60 和20 nM。ABT-263作用于不同的细胞显示出不同的细胞活性，作用于H146细胞系时EC50为110nM,而作用于H82细胞系时EC50为22 µM。ABT-737可以有效作用于四种EC50值 <400 nM的细胞系，即H146, H889, H1963, 和H1417。而两种抗ABT-737的细胞系，即H1048和H82，同样也显示出抗ABT-263的特性。^[2]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
EoL-1-cell	NXu5XmRYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{XY[2lEPTB;MD6wNFY3QSEQvF2=	NFTSW\|hUSU6JRWK=
MV-4-11	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1rDbWlEPTB;MD6wNVU5PiEQvF2=	NF31PHFUSU6JRWK=
NKM-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfzbYxKSzVyPUCuNFE3QTlizszN	MX;TRW5ITVJ?
ML-2	NHe3eHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;KTWM2OD1yLkCxPVg{KM7:TR?=	NFXKdXdUSU6JRWK=
BV-173	MkTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PMRWlEPTB;MD6wNlMyPCEQvF2=	MlS1V2FPT0WU
RS4-11	NYP4[XdET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4npRWlEPTB;MD6wNlU5PyEQvF2=	NXPp[nZ5W0GQR1XS
HL-60	NVLy[IpQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUj4NXRnUUN3ME2wMlAzQTB6IN88US=>	MV3TRW5ITVJ?
KY821	MlTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3PpbmlEPTB;MD6wNlk4PSEQvF2=	NVHKcodlW0GQR1XS
ECC10	MoW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3UfJpCUUN3ME2wMlA{Pzl{IN88US=>	M4GyXnNCVkeHUh?=
NCI-H720	NYToXZR3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVnpWnZRUUN3ME2wMlA1ODFzIN88US=>	Mn2yV2FPT0WU
QIMR-WIL	NFLQd5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fZc2lEPTB;MD6wOFI5PyEQvF2=	MmD5V2FPT0WU
KG-1	NYPENJdoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTBwMES0PFYh\|ryP	NFPrbpZUSU6JRWK=
TGW	M{D5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEX6Vo1KSzVyPUCuNFQ3OzNizszN	M4jMd3NCVkeHUh?=
ATN-1	MoHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTBwMES3N\|Mh\|ryP	NHPScXNUSU6JRWK=
RH-18	M3HnUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTzTG9KSzVyPUCuNFYxPDhizszN	M3O5[HNCVkeHUh?=
EW-18	Mon6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;pXFFKSzVyPUCuNFY5PDFizszN	NVjQXHhLW0GQR1XS
NB17	NEDrVHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGXUXXZKSzVyPUCuNFcyOjRizszN	NX7iWWx3W0GQR1XS
SK-NEP-1	MlnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7sWIxRUUN3ME2wMlA4OjF\|IN88US=>	NGXFeo9USU6JRWK=
P12-ICHIKAWA	MonSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTBwMEe3O\|gh\|ryP	M4ryPXNCVkeHUh?=
KARPAS-45	NFPKbXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M373dGlEPTB;MD6wO\|gyPSEQvF2=	MkD6V2FPT0WU
EW-3	NYf3UXl2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIC5cphKSzVyPUCuNFgxPTNizszN	MoTwV2FPT0WU
NB13	NVPuWploT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH:1OmxKSzVyPUCuNFgzODNizszN	NG\jdY9USU6JRWK=
NCI-H209	NF3PSmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\UOGlEPTB;MD6wPFcxPCEQvF2=	M4T1VHNCVkeHUh?=
NCI-H1092	NIX3UlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PUOmlEPTB;MD6xNFI4PSEQvF2=	NE\sNlNUSU6JRWK=
NH-12	NU[3SYhwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnT3TWM2OD1yLkGwO\|Q1KM7:TR?=	NWPNW49GW0GQR1XS
697	NHHtfWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfKe5NmUUN3ME2wMlExQDN7IN88US=>	NITifHlUSU6JRWK=
KE-37	MnHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVTF[nQ5UUN3ME2wMlEyOzdizszN	NXm1UI16W0GQR1XS
MOLT-4	NVn4OIx4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2X5cmlEPTB;MD6xOVE3QSEQvF2=	MUHTRW5ITVJ?
CHP-134	NI\ScHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHMVlA{UUN3ME2wMlE3OzB4IN88US=>	NHzzc2xUSU6JRWK=
D-283MED	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTBwMUe2PFYh\|ryP	Mmj1V2FPT0WU
LU-135	NWn6UY9YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHfaTmJKSzVyPUCuNVg2PTJizszN	M1f4dXNCVkeHUh?=
LU-134-A	NUHuT\|JtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWDrbHlFUUN3ME2wMlE5PjdzIN88US=>	NUDXSXRFW0GQR1XS
EM-2	MnzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTBwMUm5NVgh\|ryP	NUWwcJdxW0GQR1XS
LU-139	NUXae3NMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIDDdopKSzVyPUCuNlA1QThizszN	M2LFVXNCVkeHUh?=
ALL-PO	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTBwMkG5PFgh\|ryP	NFzm[mdUSU6JRWK=
NB12	NX7TS5ZQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFHX[25KSzVyPUCuNlMyOTVizszN	M4PrUnNCVkeHUh?=
KP-N-YN	NEjIbZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPvTWM2OD1yLkKzOVc{KM7:TR?=	MXLTRW5ITVJ?
BEN	NVy4[nhUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIjHbYlKSzVyPUCuNlM6PjhizszN	M3HYPHNCVkeHUh?=
HCC1569	NFfi[JJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml3sTWM2OD1yLkK1NVA3KM7:TR?=	M4PqfXNCVkeHUh?=
HuO9	NEKyW3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGXGemlKSzVyPUCuNlY4OTVizszN	M3TFZnNCVkeHUh?=
WM-115	Ml3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTBwMke3N\|gh\|ryP	NH20WZJUSU6JRWK=
CCRF-CEM	M2PxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{jCWGlEPTB;MD6zN\|UzQSEQvF2=	NX64V2lEW0GQR1XS
IST-SL1	M3ntNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTBwM{WzOFMh\|ryP	MXrTRW5ITVJ?
BE-13	MmixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTBwM{[0OVkh\|ryP	MkfpV2FPT0WU
COR-L88	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTBwM{[1OEDPxE1?	NGi0O41USU6JRWK=
DOHH-2	NXXSSXlWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\UTWM2OD1yLkSxNFI{KM7:TR?=	M17MPHNCVkeHUh?=
A704	MoHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTyeXZTUUN3ME2wMlQzPjdizszN	MWfTRW5ITVJ?
KNS-81-FD	M13zTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTBwNESwNVch\|ryP	Mm\DV2FPT0WU
RPMI-8226	NGnQfHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTBwNEW2OVIh\|ryP	M2HvT3NCVkeHUh?=
TGBC24TKB	M3rI[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3SzVmlEPTB;MD60OVc4QCEQvF2=	MkjiV2FPT0WU
NCI-H1304	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTBwNE[xOVch\|ryP	NGq5RW1USU6JRWK=
MOLT-13	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX;JR\|UxRTBwNE[2NVMh\|ryP	NWLWRmVZW0GQR1XS
EW-22	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfuTWM2OD1yLkS2OlcyKM7:TR?=	MULTRW5ITVJ?
MS-1	M{ixWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rpNWlEPTB;MD60Olk{OyEQvF2=	MX;TRW5ITVJ?
RMG-I	M4[4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUjYWHR5UUN3ME2wMlQ6PDZ2IN88US=>	M3W5WHNCVkeHUh?=
NTERA-S-cl-D1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTBwNUCwNVkh\|ryP	NVrTdplVW0GQR1XS
NCI-H1048	Mlv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTBwNUC5OVMh\|ryP	MnTSV2FPT0WU
SW1417	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILHUFBKSzVyPUCuOVU1OzhizszN	MUnTRW5ITVJ?
DB	M4TRVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGD5VlhKSzVyPUCuOVcxQCEQvF2=	MXTTRW5ITVJ?
MEG-01	NGnndXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;oSndKUUN3ME2wMlU5OzJizszN	NIL6bWFUSU6JRWK=
EW-13	Mkn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4j4N2lEPTB;MD61PFM1OSEQvF2=	NFOxT3pUSU6JRWK=
LAMA-84	NWfw[ZVyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTBwNUmyNFch\|ryP	NYq3XWhLW0GQR1XS
J-RT3-T3-5	NWS5ZW1FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHn6eYhKSzVyPUCuOlA5ODhizszN	M37kbnNCVkeHUh?=
MOLT-16	NHrSV4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\tTWM2OD1yLk[1NlY1KM7:TR?=	NVLKPFFVW0GQR1XS
DU-4475	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTBwNkW0Nlch\|ryP	Mkf3V2FPT0WU
HAL-01	NFH6NnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTxTWM2OD1yLkeyOVQ6KM7:TR?=	NGfCfVlUSU6JRWK=
RD	MnzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlGyTWM2OD1yLke1PFk6KM7:TR?=	MXTTRW5ITVJ?
OAW-28	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTBwN{izO{DPxE1?	MVHTRW5ITVJ?
HCC38	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTTdGRTUUN3ME2wMlgxOTlizszN	NHP4e3JUSU6JRWK=
NMC-G1	NFL0RWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFTt[\|JKSzVyPUCuPFEyOjFizszN	M3LnPHNCVkeHUh?=
EW-16	M1rpb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3viSmlEPTB;MD64NVMzQCEQvF2=	NV;5PXRkW0GQR1XS
DU-145	NWj6RYN[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUD2eIF4UUN3ME2wMlg6QTJ\|IN88US=>	MWrTRW5ITVJ?
HPAF-II	Ml2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTBwOUK2Nlgh\|ryP	NGHPO\|hUSU6JRWK=
A427	M{fpdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGTkdFRKSzVyPUCuPVMxOjJizszN	MV7TRW5ITVJ?
PA-1	MmPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXxPVJKSzVyPUCuPVU3PDJizszN	NHize5JUSU6JRWK=
OAW-42	M1PRcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\EUmlEPTB;MD65OlE1PiEQvF2=	NXHlenZWW0GQR1XS
L-428	M1rwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmT1TWM2OD1zLkCxNlUh\|ryP	MnnvV2FPT0WU
COLO-824	NEHpTYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTFwMEG3NFgh\|ryP	MYLTRW5ITVJ?
P30-OHK	NW\YdYM6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1L3fGlEPTB;MT6wOFY5QCEQvF2=	M3z4XXNCVkeHUh?=
NCI-H2170	NEfwdmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTFwME[yN{DPxE1?	NV7mOFRjW0GQR1XS
HCC2998	Mm\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlziTWM2OD1zLkC3NVM2KM7:TR?=	NWjITo9FW0GQR1XS
NB14	M{LaW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTFwMUO3OFgh\|ryP	MoHKV2FPT0WU
TGBC1TKB	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4fnc2lEPTB;MT6xOFE2OiEQvF2=	MUfTRW5ITVJ?
KP-N-YS	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTyTWM2OD1zLkG2NlM3KM7:TR?=	Moe3V2FPT0WU
CAL-120	M2ey[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHKTWM2OD1zLkG2OFI6KM7:TR?=	NF36dFNUSU6JRWK=
SBC-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LkVGlEPTB;MT6xPVA2OyEQvF2=	NYLrdmU{W0GQR1XS
C32	M{jHfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mmn0TWM2OD1zLkG5NFg5KM7:TR?=	MU\TRW5ITVJ?
HCC2157	M2jK[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXPZXNlUUN3ME2xMlE6PDl2IN88US=>	NH7WVZVUSU6JRWK=
COLO-792	NITG[5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjIO49vUUN3ME2xMlIxODdzIN88US=>	NITN[JhUSU6JRWK=
ES7	MoW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1j6eWlEPTB;MT6yO\|k2OSEQvF2=	MnvXV2FPT0WU
HEL	NHHzVW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1Pxb2lEPTB;MT6zNVAzQSEQvF2=	MlfLV2FPT0WU
ES4	M3HRfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDk[Y9KSzVyPUGuN\|Q6QThizszN	M{[0dXNCVkeHUh?=
NCI-SNU-1	MmXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVnteoVTUUN3ME2xMlM3PTV3IN88US=>	M1HhXHNCVkeHUh?=
MDA-MB-415	M2LDXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnq3TWM2OD1zLkO4PFUh\|ryP	MVfTRW5ITVJ?
NCI-H2342	M3vuOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVSz[JdYUUN3ME2xMlQxOjZ7IN88US=>	MWrTRW5ITVJ?
NB69	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonhTWM2OD1zLkS2NlcyKM7:TR?=	Mn7qV2FPT0WU
D-247MG	NV3FOXI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlK0TWM2OD1zLkWxNVIzKM7:TR?=	NYDJNG12W0GQR1XS
SCC-4	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnTpTWM2OD1zLkW5PFg4KM7:TR?=	Mn3iV2FPT0WU
HuH-7	M1f0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTFwNkeyPVMh\|ryP	M3P1WXNCVkeHUh?=
A388	NWLndG1tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrUTWM2OD1zLk[4O\|I1KM7:TR?=	MmLvV2FPT0WU
Calu-3	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;4SlZKSzVyPUGuO\|A3QTdizszN	M1f2U3NCVkeHUh?=
NCI-H1648	MlOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTxXnFKSzVyPUGuO\|E1OThizszN	NV7jdVJLW0GQR1XS
NCI-H2052	MmPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTFwN{KyNFEh\|ryP	NXT1[2lZW0GQR1XS
Ramos-2G6-4C10	MoDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;k[HltUUN3ME2xMlc{PjV4IN88US=>	NIL6VWNUSU6JRWK=
DEL	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTFwN{S2PVIh\|ryP	NYG4VGViW0GQR1XS
SNU-423	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTFwN{ixOVch\|ryP	M4jld3NCVkeHUh?=
COR-L23	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTFwN{m4O\|Qh\|ryP	MmDsV2FPT0WU
OMC-1	NFzOSWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPWT4I{UUN3ME2xMlg3ODF4IN88US=>	MkD3V2FPT0WU
EW-11	NV62PFJOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTFwOUW2OVch\|ryP	MUTTRW5ITVJ?
HSC-3	NV:2cotTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULufIZ{UUN3ME2xMlk3OzZ3IN88US=>	NVP6ZWxDW0GQR1XS
MLMA	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4H2U2lEPTB;MT65OlY4PyEQvF2=	NH35U2ZUSU6JRWK=
RCM-1	NHHTeIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NITYWWtKSzVyPUKuNFA{QTlizszN	M3n2UnNCVkeHUh?=
MFE-280	NUDRfmdYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4G0O2lEPTB;Mj6wNlg1QCEQvF2=	M{Dae3NCVkeHUh?=
ES8	NVS2VFdST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLte45KSzVyPUKuNlU1PzFizszN	M4LHSHNCVkeHUh?=
TE-11	NFPNUVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTJwMkm0O\|Mh\|ryP	MXXTRW5ITVJ?
HuO-3N1	MmHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4ewUGlEPTB;Mj60PFc5KM7:TR?=	NU\l[WFIW0GQR1XS
MHH-NB-11	NG\HVmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnHWHBKSzVyPUKuOVEyPThizszN	Mn3vV2FPT0WU
TGBC11TKB	NIrEXXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV7qO\|hVUUN3ME2yMlU4PjhzIN88US=>	MV3TRW5ITVJ?
HOP-92	NGr3cZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\wOWlEPTB;Mj61PFc1OyEQvF2=	NXn6TXQ2W0GQR1XS
IGR-1	NGjEV3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2jNUmlEPTB;Mj62NlA{PSEQvF2=	NIO1UmpUSU6JRWK=
GOTO	Mof6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV2zR5YyUUN3ME2yMlY2Ozd5IN88US=>	NXHET5NiW0GQR1XS
NCI-H1650	NF7hXI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTJwN{KyNVUh\|ryP	NHTKe5hUSU6JRWK=
NCI-H1581	MnXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTJwN{m2PFEh\|ryP	Mn6wV2FPT0WU
NCI-H2405	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\DTWM2OD1{LkiyO\|gzKM7:TR?=	NInDUZRUSU6JRWK=
U-118-MG	MnPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHzd5JKSzVyPUKuPVY1QTFizszN	Ml3qV2FPT0WU
DoTc2-4510	M4q1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NETqNnhKSzVyPUOuNFE1OTdizszN	MnT3V2FPT0WU
NCI-H596	MoezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEKwe4JKSzVyPUOuNFQ6QTdizszN	M4fyd3NCVkeHUh?=
MPP-89	Mn22S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFnnOlZKSzVyPUOuNFU3PjZizszN	MVPTRW5ITVJ?
GCIY	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVvJR\|UxRTNwMkC0PVEh\|ryP	MVfTRW5ITVJ?
SW626	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWXYOohMUUN3ME2zMlI1PTR\|IN88US=>	MVPTRW5ITVJ?
OCI-AML2	Ml[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH3O[pNKSzVyPUOuN\|EzPzJizszN	Mo\RV2FPT0WU
NBsusSR	MnT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLaTWM2OD1\|LkO0PVM5KM7:TR?=	MnjBV2FPT0WU
AN3-CA	M{XhS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUD5bVlvUUN3ME2zMlQ1OjN6IN88US=>	MkHQV2FPT0WU
EFM-19	NGrhRnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PqSGlEPTB;Mz60PFM{QSEQvF2=	NWXwNXVUW0GQR1XS
RVH-421	NFzPfYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnWyTWM2OD1\|LkW2PFc4KM7:TR?=	MmfnV2FPT0WU
5637	NXS3Uo9NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXf0VpY6UUN3ME2zMlYyOTB\|IN88US=>	NF;oO3VUSU6JRWK=
PANC-08-13	NFH1eYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1faNmlEPTB;Mz62N\|Q4OiEQvF2=	M3vyTXNCVkeHUh?=
H9	MlfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3n3bmlEPTB;Mz62O\|E1PCEQvF2=	NUnYeolLW0GQR1XS
KARPAS-299	Ml7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHHBXWJKSzVyPUOuOlc{PjFizszN	Mo\hV2FPT0WU
TE-5	NVPXV4xsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVXJR\|UxRTNwN{C3NFkh\|ryP	NHPFfnhUSU6JRWK=
NOS-1	MnzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTLO2VKSzVyPUOuO\|k5OzRizszN	MVHTRW5ITVJ?
HH	NUXURoEyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUe4[lVZUUN3ME2zMlg{QDZ6IN88US=>	Mn7CV2FPT0WU
769-P	MkjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTNwOEm1NUDPxE1?	MVnTRW5ITVJ?
CHP-212	NVWyd5BJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTNwOUK1OFkh\|ryP	MVvTRW5ITVJ?
NCI-H82	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnTUZRKSzVyPUOuPVU6OzZizszN	MkLoV2FPT0WU
Mo-T	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2HQSWlEPTB;ND6wOFMyOiEQvF2=	MoTxV2FPT0WU
BB65-RCC	M4TG[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHnMOZdKSzVyPUSuNFQ{QTlizszN	M2\rcHNCVkeHUh?=
SW1990	M3PlV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYrjdmVSUUN3ME20MlA2QTB6IN88US=>	MmLBV2FPT0WU
LK-2	NEHXT29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3v1PWlEPTB;ND6xNVI6OyEQvF2=	NUP6OIpOW0GQR1XS
ES5	NIDrPHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjPTWM2OD12LkGzPVg2KM7:TR?=	MWDTRW5ITVJ?
JVM-3	NVLlTWVVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnn[HV5UUN3ME20MlE5OjJ{IN88US=>	MULTRW5ITVJ?
RPMI-7951	NYrC[mdlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTRwMkK0NVMh\|ryP	M3HkU3NCVkeHUh?=
Calu-6	MnSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkXaTWM2OD12LkK3PFgyKM7:TR?=	NF60UFRUSU6JRWK=
LC-2-ad	MojVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;RN4ZKSzVyPUSuNlk2PjhizszN	NV;yU\|U{W0GQR1XS
SW954	MoXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1u3bWlEPTB;ND6yPVY3KM7:TR?=	NUfHXIVjW0GQR1XS
H-EMC-SS	NVTL[mdOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHYeYRmUUN3ME20MlMyQDNzIN88US=>	NFn1VmdUSU6JRWK=
ES3	NUjwUWVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTRwM{W0OFEh\|ryP	MX;TRW5ITVJ?
no-11	Ml;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\rRm5bUUN3ME20MlM2PTV2IN88US=>	MXvTRW5ITVJ?
LAN-6	NHnre4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3H6N2lEPTB;ND60OVE5QSEQvF2=	NIXSeWZUSU6JRWK=
FTC-133	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnyzTWM2OD12LkWzPVUh\|ryP	MYnTRW5ITVJ?
8505C	MmDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVf4Z21sUUN3ME20MlU1OjNizszN	MYnTRW5ITVJ?
SW620	MorDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XUcmlEPTB;ND61O\|A2PyEQvF2=	M3;leXNCVkeHUh?=
BCPAP	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXK0[I4yUUN3ME20MlY{PDhzIN88US=>	NHzaN3RUSU6JRWK=
SK-LU-1	M4f4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTRwNk[wPFkh\|ryP	Mo\iV2FPT0WU
NCI-H1623	NH\EOndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnpVGFKSzVyPUSuO\|AzOjhizszN	NVfS[ZhIW0GQR1XS
C2BBe1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M37CWmlEPTB;ND63OFAxQCEQvF2=	MWXTRW5ITVJ?
GP5d	NXLDeIw2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnuTWM2OD12Lke4N\|g5KM7:TR?=	Mm\RV2FPT0WU
NB6	MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkTaTWM2OD12Lki2NlA1KM7:TR?=	M3TDPXNCVkeHUh?=
MDA-MB-157	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjtOllKSzVyPUSuPFg4PiEQvF2=	NGTzSJNUSU6JRWK=
UMC-11	NGn6blVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jPTmlEPTB;ND64PFk3PCEQvF2=	MnLJV2FPT0WU
HCC1419	NXvTXmtqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;obpBKSzVyPUSuPVAxPjNizszN	NXfnTlRkW0GQR1XS
NCI-H2029	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Moj2TWM2OD12Lkm0NVg2KM7:TR?=	NIXYWWxUSU6JRWK=
LXF-289	M1rvdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfvOoVKSzVyPUWuNFM4OTlizszN	MkK1V2FPT0WU
KINGS-1	NVfaZZFrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlSyTWM2OD13LkC3O\|Q1KM7:TR?=	NELBd45USU6JRWK=
HD-MY-Z	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoezTWM2OD13LkKzPVY6KM7:TR?=	MWTTRW5ITVJ?
ESS-1	M4H5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XSWGlEPTB;NT6yOVU6PyEQvF2=	MYnTRW5ITVJ?
GI-1	NULi[WZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnyxTWM2OD13LkK3PVI3KM7:TR?=	NYK0N5ZTW0GQR1XS
RPMI-2650	NH63PYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4nJbWlEPTB;NT6zOlE3KM7:TR?=	MXzTRW5ITVJ?
IA-LM	MkTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4S5SmlEPTB;NT6zPVg4OSEQvF2=	NU\RR5lXW0GQR1XS
KP-4	MnrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXZTWM2OD13LkS2N\|M1KM7:TR?=	MUfTRW5ITVJ?
G-402	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI[3Z2tKSzVyPUWuOVE5PjVizszN	MX\TRW5ITVJ?
OS-RC-2	NYP2[\|NqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;sTWM2OD13LkWyOlA1KM7:TR?=	MkG5V2FPT0WU
NCI-H1155	NXrBOmczT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\H[\|ZKSzVyPUWuOVQ6PTVizszN	MXLTRW5ITVJ?
OE19	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWXJR\|UxRTVwNki2NlQh\|ryP	NVfh[2lJW0GQR1XS
U-2-OS	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX63cZd1UUN3ME21Mlg6ODF\|IN88US=>	NXP2O\|ZEW0GQR1XS
SCC-15	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTVwOUO2OlIh\|ryP	NF\nO5JUSU6JRWK=
NCI-H630	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2P0emlEPTB;NT65PVQxPCEQvF2=	NHvkemNUSU6JRWK=
PFSK-1	NVHOc49LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvuTWM2OD14LkC1NlU6KM7:TR?=	NYnUNlhuW0GQR1XS
NCI-H1770	NIfLc5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTZwMkC4O\|Qh\|ryP	NXLZWW5lW0GQR1XS
SK-MEL-3	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkjITWM2OD14LkSyPVE2KM7:TR?=	M4DwRnNCVkeHUh?=
LB1047-RCC	NYnQcHU5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nScWlEPTB;Nj60O\|YzPSEQvF2=	M1npcXNCVkeHUh?=
NCI-H446	NI\qPFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofLTWM2OD14Lk[yPVI2KM7:TR?=	NI\Eb2NUSU6JRWK=
SW780	NEHnT29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTZwN{CxPFUh\|ryP	M1;lbnNCVkeHUh?=
NEC8	NGT5d2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;ucZJsUUN3ME22Mlc3PjNizszN	NFnUVIZUSU6JRWK=
NOMO-1	NX;jepBIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTZwN{ixNVEh\|ryP	M2HMWnNCVkeHUh?=
COLO-668	M4HQcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHnnc5FKSzVyPU[uPFQ{QDdizszN	NWTQPYNRW0GQR1XS
MC116	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTSeZBCUUN3ME22Mlk{QDl5IN88US=>	M1fXWXNCVkeHUh?=
HCC1937	NIrmc3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3LxXmlEPTB;Nj65PVI2OSEQvF2=	NVXaS21DW0GQR1XS
NCI-N87	NXnNNpBmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTdwMUmyPVMh\|ryP	NV30Om5DW0GQR1XS
COLO-320-HSR	M{W4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEXBNXRKSzVyPUeuNlI4OzhizszN	NEi0R4NUSU6JRWK=
HCC1806	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\MUot3UUN3ME23MlI3ODR2IN88US=>	MVPTRW5ITVJ?
OVCAR-3	NXTlWWw1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jCc2lEPTB;Nz6zN\|A{QCEQvF2=	M{n3WnNCVkeHUh?=
NUGC-3	M2DUNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPHb\|AyUUN3ME23MlM6Pjl2IN88US=>	NEfMU3lUSU6JRWK=
SW1783	NHjzU5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlL6TWM2OD15LkSzNVc2KM7:TR?=	MUnTRW5ITVJ?
GCT	NIO3SFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTdwNU[5NFYh\|ryP	M1TCWHNCVkeHUh?=
NCI-H2126	NUTxcZpwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYCxdplUUUN3ME23Mlc{PjJ3IN88US=>	NVnoSGw4W0GQR1XS
MEL-HO	NITaXZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmLpTWM2OD15Lke3NFU1KM7:TR?=	Mo\pV2FPT0WU
CAPAN-1	NU\UdVdQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DxNmlEPTB;Nz63O\|M2PyEQvF2=	NGrwRXBUSU6JRWK=
SW756	NUHDS5VWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{fUbGlEPTB;Nz63PFM{OyEQvF2=	NH7OXnFUSU6JRWK=
SKG-IIIa	MnLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWm3UJFbUUN3ME23MlgyQDl{IN88US=>	MWHTRW5ITVJ?
HCE-T	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmDBTWM2OD15Lki3O\|g{KM7:TR?=	M3PiNnNCVkeHUh?=
Ca-Ski	NUHFUnZQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWrxUWExUUN3ME23Mlk6Ozh\|IN88US=>	M33MXnNCVkeHUh?=
COLO-684	NWPh[ldRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHMV4xWUUN3ME24MlAyQDF6IN88US=>	M1PDOXNCVkeHUh?=
KYSE-70	NHHaUJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4G2W2lEPTB;OD6wO\|czQSEQvF2=	MnLBV2FPT0WU
TI-73	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILPT2dKSzVyPUiuNlU5PTFizszN	NEXCRnJUSU6JRWK=
BT-20	NXX0[HM6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLxTWM2OD16LkK2NFUzKM7:TR?=	NVjDVG1nW0GQR1XS
MHH-ES-1	NFjMe4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInjUnhKSzVyPUiuOVE5OzRizszN	MULTRW5ITVJ?
TE-12	MnvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlf1TWM2OD16LkW5PVMyKM7:TR?=	MX3TRW5ITVJ?
YH-13	M4rCNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTpcoloUUN3ME24MlYyODB6IN88US=>	MojsV2FPT0WU
SF126	NHTPXmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUPJR\|UxRThwOEO4OlUh\|ryP	NHLJ[\|lUSU6JRWK=
J82	NITJdo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M17oNmlEPTB;OD65NFA{QCEQvF2=	MorkV2FPT0WU
RCC10RGB	NXn0OHVXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUT4dJoyUUN3ME24Mlk6PTZzIN88US=>	M2nkV3NCVkeHUh?=
SK-UT-1	NH7JeINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M13uZ2lEPTB;OT6wOFk1PSEQvF2=	Mm\MV2FPT0WU
LB2241-RCC	NVHVPWF{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTlwMUmxN\|ch\|ryP	M2G0NnNCVkeHUh?=
LB996-RCC	NGHucodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDmb4JJUUN3ME25MlE6QDlizszN	M2HQe3NCVkeHUh?=
EPLC-272H	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELEZ3FKSzVyPUmuN\|c3PTdizszN	MoTTV2FPT0WU
CTV-1	NXzNV5dOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3SxOGlEPTB;OT61OlU{OiEQvF2=	M{noTnNCVkeHUh?=
HSC-2	NGXZc3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHXNWGtKSzVyPUmuOVc2PSEQvF2=	Mm\tV2FPT0WU
SK-MEL-28	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHqNYN2UUN3ME25MlYyQDl\|IN88US=>	MlG3V2FPT0WU
MMAC-SF	M{LmNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1rBWGlEPTB;OT62PFc2KM7:TR?=	M4LkTnNCVkeHUh?=
CP50-MEL-B	MkH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfLTWM2OD17Lke1O\|gzKM7:TR?=	M3i3XXNCVkeHUh?=
HT-1080	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTlwN{e3N\|kh\|ryP	NYLPUnRIW0GQR1XS
HEC-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkfYTWM2OD1zMD6zN\|UzKM7:TR?=	NHLQbZlUSU6JRWK=
AGS	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1T5SWlEPTB;MUCuN\|c1KM7:TR?=	NVrpbo9LW0GQR1XS
GAMG	NE[3dGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYi4fVREUUN3ME2xNE42OTZ{IN88US=>	NXHzO3B1W0GQR1XS
SW48	M1;JWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M37Jc2lEPTB;MUCuOVE5QSEQvF2=	M2S5dnNCVkeHUh?=
U031	M3y1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTFyLkW5NFgh\|ryP	NV;uXIduW0GQR1XS
OVCAR-5	MkLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2nDSGlEPTB;MUCuOlQzQSEQvF2=	NVHoSYZOW0GQR1XS
SF295	Mm\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzO[G9EUUN3ME2xNE43PzB2IN88US=>	NIq3R3FUSU6JRWK=
BHT-101	M4GyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{j3WGlEPTB;MUCuO\|E4PyEQvF2=	NXXY[XJ4W0GQR1XS
VMRC-RCZ	MmXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\GTWM2OD1zMT6zNlAyKM7:TR?=	MmjkV2FPT0WU
ACHN	M2rQb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\1ZWlEPTB;MUGuOFIyOSEQvF2=	MV\TRW5ITVJ?
NCI-H526	NIm5TXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTFzLkWwOFMh\|ryP	M3P0c3NCVkeHUh?=
MN-60	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTFzLkWzPUDPxE1?	M4Hvb3NCVkeHUh?=
NCI-H2291	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTFzLkW0OlYh\|ryP	MoXaV2FPT0WU
SCC-25	Mlu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTFzLke1OVYh\|ryP	MoW4V2FPT0WU
SK-MEL-2	NY\NVFBHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4fhT2lEPTB;MUGuO\|Y{PyEQvF2=	MWXTRW5ITVJ?
SN12C	NIDM[3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF61NFdKSzVyPUGxMlk{PTVizszN	MmfpV2FPT0WU
NCI-H69	NXP1fYFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXqbHVlUUN3ME2xNk41OjN2IN88US=>	M2fLcXNCVkeHUh?=
ME-180	M3Oxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTF{LkewOVQh\|ryP	MVLTRW5ITVJ?
MC-IXC	M4T5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTF{Lke1NVgh\|ryP	NVT5NXBEW0GQR1XS
NCI-H2347	M1vIUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;qSolKSzVyPUGyMlc3OTRizszN	M3Ta[HNCVkeHUh?=
M059J	M1nKXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3TaVWlEPTB;MUKuO\|czPyEQvF2=	NVraSFdnW0GQR1XS
A2058	Ml3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPOTWM2OD1zMj64OlgyKM7:TR?=	NEHweI1USU6JRWK=
VA-ES-BJ	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTF{Lki3PFUh\|ryP	NYrvfHRrW0GQR1XS
Ca9-22	NH;uNYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTF{Lkm0OVEh\|ryP	NIH0S4dUSU6JRWK=
KNS-42	M13hcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\ofGlEPTB;MUKuPVk5PCEQvF2=	MlLuV2FPT0WU
LoVo	MoPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfUcpFKSzVyPUGzMlI{OTNizszN	M3;3cnNCVkeHUh?=
AM-38	NV7lOldVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIjkTIRKSzVyPUGzMlI2PjZizszN	NHjsV5pUSU6JRWK=
NB5	NHWxeplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUPJR\|UxRTF\|LkO3OVIh\|ryP	NVTT[oFQW0GQR1XS
L-363	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTF\|LkSwN\|Mh\|ryP	MVrTRW5ITVJ?
SK-MEL-30	MnvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnG0TWM2OD1zND6wOlQ2KM7:TR?=	MXjTRW5ITVJ?
NCI-H1563	NVzkWmpDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYq5XpBZUUN3ME2xOE43ODN7IN88US=>	NI[wdZNUSU6JRWK=
NCI-H2228	NI\iU4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWW0eG5jUUN3ME2xOE43ODd5IN88US=>	NEfEbnlUSU6JRWK=
MFM-223	MlnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUD1d5c2UUN3ME2xOU4yQDF\|IN88US=>	MYTTRW5ITVJ?
LB831-BLC	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTF3LkK3Olch\|ryP	MXnTRW5ITVJ?
SW872	NInlWGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PkPGlEPTB;MUWuN\|A5PiEQvF2=	NUj5[m17W0GQR1XS
NCI-H522	NWixXVN4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVXQS4tsUUN3ME2xOU4{OzB4IN88US=>	NYm1UZR4W0GQR1XS
EW-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrUNXFKSzVyPUG1MlU1PjJizszN	MV3TRW5ITVJ?
HN	M2XuWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4nmd2lEPTB;MUWuOVk1OiEQvF2=	NVL6c4N3W0GQR1XS
SW837	MlHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PoWGlEPTB;MUWuO\|g1PyEQvF2=	MmnlV2FPT0WU
SCC-9	MoP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3[0NGlEPTB;MUWuPFEyPCEQvF2=	M1L4ZnNCVkeHUh?=
MKN7	M{WyU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1Xa[WlEPTB;MUWuPVc{OiEQvF2=	M4XvZnNCVkeHUh?=
KYSE-410	NEfreXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NITHTYZKSzVyPUG2MlU6OSEQvF2=	MULTRW5ITVJ?
SK-N-DZ	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTF4Lk[xNVYh\|ryP	MlvBV2FPT0WU
COR-L105	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVvHVVF1UUN3ME2xOk43PTJ6IN88US=>	M{fkTnNCVkeHUh?=
LB2518-MEL	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MojZTWM2OD1zNj64N\|g6KM7:TR?=	MUPTRW5ITVJ?
OVCAR-4	NVrsZpN2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1Lpc2lEPTB;MU[uPFg3OiEQvF2=	M2LydHNCVkeHUh?=
TK10	NYTGc2F[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTF4Lkm0O\|Mh\|ryP	NYHqWWJ1W0GQR1XS
KNS-62	NWjONnBLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3fnZWlEPTB;MU[uPVc4PyEQvF2=	MWLTRW5ITVJ?
RPMI-8866	MlSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M13aWmlEPTB;MUeuNVc{OiEQvF2=	MX;TRW5ITVJ?
HuP-T4	NFzhRXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnEZldKSzVyPUG3MlI1QTVizszN	NWTOTJhKW0GQR1XS
CGTH-W-1	Mn7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFrpNYxKSzVyPUG3MlUzOTlizszN	MkDSV2FPT0WU
T-24	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7S[opKSzVyPUG3MlU{PDdizszN	NHz4ZWJUSU6JRWK=
HT-3	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{POW2lEPTB;MUeuOVkyPCEQvF2=	NYfUV2VRW0GQR1XS
KS-1	MoHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIG1XmxKSzVyPUG3MlY4OyEQvF2=	M4\aTnNCVkeHUh?=
NCI-H1792	MkjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHZTWM2OD1zNz63PVgh\|ryP	MVTTRW5ITVJ?
ABC-1	NFqyU3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYnWbJI6UUN3ME2xO{45OTRzIN88US=>	M1PXcXNCVkeHUh?=
BPH-1	NXrNRpB{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGHuOZZKSzVyPUG4MlE3QDVizszN	MWjTRW5ITVJ?
A431	NXPMO2I5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PKemlEPTB;MUiuOFEzPyEQvF2=	MkXwV2FPT0WU
T98G	NHXmVHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\UTWM2OD1zOD61NVU4KM7:TR?=	M{HVenNCVkeHUh?=
BHY	MnjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHTVR2tKSzVyPUG4Mlg3QSEQvF2=	NV7qfWk{W0GQR1XS
Capan-2	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVf6dlVEUUN3ME2xPE46ODd6IN88US=>	NIL6fJVUSU6JRWK=
MDA-MB-175-VII	M1HUWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUfNSFlLUUN3ME2xPE46OjB7IN88US=>	M3PvUXNCVkeHUh?=
CAL-27	NIXMTo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXzFS5lVUUN3ME2xPU4xPDh5IN88US=>	NGLMS\|RUSU6JRWK=
AsPC-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGi4eVlKSzVyPUG5Mlg3PTdizszN	MX;TRW5ITVJ?
KU812	NWT4W29LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHO5b5dKSzVyPUG5Mlk2PzNizszN	M4\ufHNCVkeHUh?=
NCI-H441	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HNfWlEPTB;MkCuNFAyKM7:TR?=	NF3hR41USU6JRWK=
Mewo	M4T4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWrofGhWUUN3ME2yNE4yOjh6IN88US=>	M2fLN3NCVkeHUh?=
SK-MEL-24	NFLsc3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rGN2lEPTB;MkCuNVQ4PyEQvF2=	MXLTRW5ITVJ?
NCI-H727	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3vtZ2lEPTB;MkCuNlcxPCEQvF2=	NHr3VHJUSU6JRWK=
EKVX	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTJyLk[wOkDPxE1?	Mmf2V2FPT0WU
RT-112	NFTsbIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTWPJZKSzVyPUKwMlYyOjJizszN	MV;TRW5ITVJ?
CAMA-1	M3XZOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV2xNIRuUUN3ME2yNE46QDB\|IN88US=>	MWTTRW5ITVJ?
SW900	NXjVNXNlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnDTWM2OD1{MT6wNVQ6KM7:TR?=	NFHsXJNUSU6JRWK=
NCI-H23	M2SycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTJzLkGyO\|ch\|ryP	MYXTRW5ITVJ?
SK-PN-DW	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVzl[4c6UUN3ME2yNU4yPjR7IN88US=>	M4m2UXNCVkeHUh?=
BB30-HNC	M{jwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknVTWM2OD1{MT6yO\|Q2KM7:TR?=	MnXhV2FPT0WU
VM-CUB-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jDOGlEPTB;MkGuN\|U{PiEQvF2=	M4PwdnNCVkeHUh?=
IST-MEL1	NUnpeWp6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTJzLkO2PVIh\|ryP	MlfoV2FPT0WU
CTB-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTJzLkS3OVUh\|ryP	MmHBV2FPT0WU
LCLC-103H	M2LWeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHPcmlKSzVyPUKyMlE2QDJizszN	NFvje5JUSU6JRWK=
PANC-03-27	NXfQSJpnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTJ{LkWxOlkh\|ryP	MUTTRW5ITVJ?
HTC-C3	NX:0cHpkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPuSHFRUUN3ME2yNk42PTV3IN88US=>	M4TKR3NCVkeHUh?=
TE-8	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTJ\|LkK1OlUh\|ryP	MmjPV2FPT0WU
NCI-H292	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTJ3LkO1N\|Yh\|ryP	NUG2T\|JNW0GQR1XS
COLO-680N	NYKxcYM5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIm1fHBKSzVyPUK1MlY{OjlizszN	NEXCNo9USU6JRWK=
KYSE-520	Mn3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo\ITWM2OD1{NT62OFQh\|ryP	M17oNHNCVkeHUh?=
NB10	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\wR49KSzVyPUK2MlMyOTdizszN	MoTLV2FPT0WU
NCI-H661	MmjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7UTWM2OD1{Nj60O\|E{KM7:TR?=	NH7xT5JUSU6JRWK=
GMS-10	NH[yUmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnCcIpKSzVyPUK2Mlg3OzhizszN	MWrTRW5ITVJ?
NCI-H2122	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkTKTWM2OD1{Nj65PVk5KM7:TR?=	MoLQV2FPT0WU
OVCAR-8	Mke3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIjJR5dKSzVyPUK3MlA3OzhizszN	MmrOV2FPT0WU
DJM-1	MmDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnrLTWM2OD1{Nz6xOFU1KM7:TR?=	MXHTRW5ITVJ?
UACC-893	NHfYN4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTJ5Lkm4O\|gh\|ryP	M4e5VnNCVkeHUh?=
C8166	M1fTNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTJ6Lk[5N\|gh\|ryP	MUXTRW5ITVJ?
NCI-H1693	M2[wZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjvTWM2OD1{OD62PVc2KM7:TR?=	Mk[1V2FPT0WU
TYK-nu	NHjoV49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTNyLkCzOFUh\|ryP	Mkj2V2FPT0WU
SW1710	Mn7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHPTWM2OD1\|MD6xNlYh\|ryP	MofkV2FPT0WU
A375	NXrpbm5XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTNyLkOyOFMh\|ryP	M12ybHNCVkeHUh?=
HMV-II	M{jQOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTNzLkO1PVIh\|ryP	NIDKNlFUSU6JRWK=
NCI-H2087	MoW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofGTWM2OD1\|MT62N\|UzKM7:TR?=	NYizWIhwW0GQR1XS
CAL-54	M3HPO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTNzLkeyOFEh\|ryP	NHfSZpRUSU6JRWK=
HCC70	MmLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7UcpNWUUN3ME2zNk4yOzh5IN88US=>	NVLXPFVyW0GQR1XS
ES1	NXHWe\|B7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTN{LkOwOlIh\|ryP	M4ftbHNCVkeHUh?=
NCI-H1355	NWm3WmhlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTN\|LkKwOEDPxE1?	MluwV2FPT0WU
CFPAC-1	NYjSZlh3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvqbmlKSzVyPUOzMlI{OzJizszN	M{PrPHNCVkeHUh?=
MKN28	NVfPd4ZST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTN\|LkO4NFkh\|ryP	MYDTRW5ITVJ?
HDLM-2	MonuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV72ZlA5UUN3ME2zN{43QTNzIN88US=>	MmrFV2FPT0WU
PANC-10-05	MmfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTN2LkGwNVQh\|ryP	Ml\QV2FPT0WU
SAS	NGPuclVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXqyWYhKUUN3ME2zOE41PTZ3IN88US=>	MV7TRW5ITVJ?
HCC1395	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4fvWGlEPTB;M{SuO\|E5PiEQvF2=	MVnTRW5ITVJ?
8305C	MoDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2Prc2lEPTB;M{WuPFQyPSEQvF2=	M{j3dnNCVkeHUh?=
KM12	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\6d2lKSzVyPUO2Mlc2PDdizszN	M1LUbHNCVkeHUh?=
SW1116	NGHUfIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1nKc2lEPTB;M{euOVk6OiEQvF2=	NXnvVJI3W0GQR1XS
SK-MEL-1	NUf4ZnV{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jQV2lEPTB;M{iuN\|M5QSEQvF2=	M4DsTXNCVkeHUh?=
HCC2218	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHXjRmlKSzVyPUO4MlY2OTlizszN	MlTDV2FPT0WU
T84	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXGXHFKSzVyPUO4Mlc1ODlizszN	NYr4S5FiW0GQR1XS
ETK-1	NEXLU49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHONHFKSzVyPUO5MlAzOiEQvF2=	NHv6V25USU6JRWK=
COLO-800	NFLSXYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1GwSGlEPTB;M{muN\|g3QCEQvF2=	NI\mPIRUSU6JRWK=
CAL-12T	NHHTWoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYiwUnZYUUN3ME2zPU42OjhzIN88US=>	MmPkV2FPT0WU
ACN	Mnn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHjH[JhKSzVyPUSwMlQ6OTFizszN	NHu2bWRUSU6JRWK=
SJSA-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVToeGI5UUN3ME20NU4yPTl4IN88US=>	NFPROndUSU6JRWK=
PSN1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlTDTWM2OD12MT6xO\|Q6KM7:TR?=	NEHpZ\|hUSU6JRWK=
D-566MG	MliwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFX1T5FKSzVyPUSxMlIxQDZizszN	MnvuV2FPT0WU
EGI-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTR{LkSyPEDPxE1?	M4CzfHNCVkeHUh?=
A204	M3;kXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjZd4NKSzVyPUSyMlY{QDhizszN	MWHTRW5ITVJ?
Saos-2	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2T1eGlEPTB;NEKuPFM3QSEQvF2=	Ml;KV2FPT0WU
SNU-C2B	NIPaS4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTR\|Lk[4O\|gh\|ryP	MmC2V2FPT0WU
HLE	M3fsV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zRO2lEPTB;NESuNFg2PiEQvF2=	MYPTRW5ITVJ?
SW1463	M3THNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXGWVRKSzVyPUS0Mlk6PzFizszN	MoXyV2FPT0WU
DSH1	M{HvZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYPLdHZJUUN3ME20OU4xODN\|IN88US=>	NV;ObFZXW0GQR1XS
MCF7	NEnlZ3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1uzb2lEPTB;NEWuOVA2OSEQvF2=	M1X5dnNCVkeHUh?=
K5	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXGz[oJ6UUN3ME20OU46PDB3IN88US=>	NXrT[lZpW0GQR1XS
NCI-H358	MkTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4DTZWlEPTB;NEeuNlE2KM7:TR?=	NFvrSldUSU6JRWK=
NCI-H2030	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVvJR\|UxRTR5LkKzO\|Qh\|ryP	MV7TRW5ITVJ?
SW948	MkjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fjcGlEPTB;NEeuOFY1KM7:TR?=	MXHTRW5ITVJ?
BALL-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTR5Lk[xOlgh\|ryP	NFrQc3FUSU6JRWK=
TE-9	Mk\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVqzWFF7UUN3ME20O{46PThzIN88US=>	NUn4[VNHW0GQR1XS
SK-N-FI	M1HFd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTR6LkCzOVgh\|ryP	NHftcYpUSU6JRWK=
KALS-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\UTWM2OD12OD6xNlg6KM7:TR?=	M3TNWHNCVkeHUh?=
HO-1-N-1	MmPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;OTWM2OD12OD63OFQ2KM7:TR?=	MX3TRW5ITVJ?
NCI-H2452	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTR7LkGxOVIh\|ryP	M4m3UXNCVkeHUh?=
OC-314	NV3EeG04T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnufHV7UUN3ME20PU43QDN2IN88US=>	MoDHV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	STAT3 / pSTAT3 / STAT6 / pSTAT6 / Mcl-1 / Cleaved Mcl-1 / Bcl-xl / Bim / puma / Bik / Bax / PARP / c-Myc; PubMed: 26811457 Proc Natl Acad Sci U S A (A) Western blot analysis of expressions of STAT3/p-STAT3 and STAT6/p-STAT6 as well as antiapoptotic members (Bcl-2, Bcl-xL, and Mcl-1) after 48 h of treatments in HDLM-2 cells. (B) Western blot analysis of expressions of proapoptotic proteins (Bim, Puma, Bik, Bax, and p-Bad) as well as caspase cascade molecules (PARP and c-Myc) after 48 h of treatments. β-Actin was used as an input control. caspase3 / cleaved caspase 3; PubMed: 24481442 Cell Death Dis (b) (i) N/TERT, (ii) SINCE and (iii) SINEG2 cells were either untreated (0 μM/DMSO) or treated with increasing doses of Navitoclax (ABT-263; 0.025–30 μM) and were incubated for 24 h. Next, cells were collected and whole-cell lysates were prepared and immunoblotted against anti-full-length Caspase 3 (∼35 kDa) antibody, whereas β-actin (∼42 kDa) was used as a protein-loading control. Apoptosis was assessed through detecting the cleaved bands of Caspase-3 (∼19, 17 kDa).	26811457 24481442
Growth inhibition assay	Cell viability; PubMed: 25685063 Cancer Cell Int (C) Hcc827, (D) H292, and (E) H1993 cells were treated with increasing concentrations of albendazole or mebendazole in the presence of navitoclax (0, 1, 2, and 4 μM). Viability was determined after 1 day.	25685063

体内研究

用ABT-263处理H345移植瘤模型，按动物体重，每千克每天处理10mg ABT-263，结果肿瘤生长抑制率达80% ，肿瘤体积减小了50%以上，显示出ABT-263极强的抗癌效果。ABT-263作用于非小细胞肺癌和急性淋巴细胞白血病的移植瘤模型时，每天单独口服，结果显示肿瘤完全衰退。ABT-263单独作用于B-细胞淋巴瘤和多发性骨髓瘤的移植瘤模型时效果不明显，但是可以显著增强临床其他相关用药的药性。^[2]

激酶实验： ^[1]	- 合并激酶实验: 用竞争性荧光偏振检测测定ABT-263 作用于Bcl-2 家族不同亚型的Ki值或者IC50值。使用如下的肽探针对或者蛋白对：f-bad (1 nM) 和Bcl-xL (6 nM), f-Bax (1 nM) 和Bcl-2 (10 nM), f-Bax (1 nM) 和Bcl-w (40 nM), f-Noxa (2 nM)和Mcl-1 (40 nM), 及f-Bax (1 nM) 和Bcl-2-A1 (15 nM)。用时间分辨荧光共振能转移法测定ABT-263和Bcl-xL作用的结合紧密度。1 nM 用His标记的Bcl-xL 与200 nM f-Bak,及 1 nM Tb标记的His抗体混合, 然后在室温下处理30分钟。
细胞实验： ^[1]	- 合并 Cell lines: SCLC 细胞系 Concentrations: 0-1 μM Incubation Time: 48小时 Method: 人类肿瘤细胞系在37^oC 含5% CO₂环境下获得，SCLC 细胞系培养在RPMI 1640培养基中，培养基包含10% 胎牛血清, 1% 丙酮酸钠, 25 mM HEPES, 4.5 g/L葡萄糖, 1% 青霉素/链霉素。用含有10% FBS和1% 青霉素/链霉素的RPMI 1640培养基培养白血病和淋巴癌细胞系。细胞在96孔板上处理48小时，最终体积达到100ul。在体外测试ABT-263的细胞毒性。 (Only for Reference)
动物实验： ^[1]	- 合并 Animal Models: C.B.-17严重联合免疫缺陷-米黄鼠 Dosages: 100 mg/kg/d Administration: 口服处理 (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMSO	100 mg/mL (102.6 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+corn oil	7mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Navitoclax (ABT-263) SDF

分子量	974.61
化学式	C₄₇H₅₅ClF₃N₅O₆S₃
CAS号	923564-51-6
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04480086	Not yet recruiting	Drug: Mivebresib\|Drug: Navitoclax\|Drug: Ruxolitinib	Myelofibrosis (MF)	AbbVie	July 31 2020	Phase 1
NCT04454658	Not yet recruiting	Drug: ABBV-744\|Drug: Navitoclax\|Drug: Ruxolitinib	Myelofibrosis (MF)	AbbVie	July 14 2020	Phase 1
NCT04041050	Recruiting	Drug: Navitoclax\|Drug: Ruxolitinib	Myeloproliferative Neoplasm	AbbVie	November 8 2019	Phase 1
NCT03181126	Active not recruiting	Drug: Navitoclax\|Drug: Chemotherapy\|Drug: Venetoclax	Acute Lymphoblastic Leukemia (ALL)\|Lymphoblastic Lymphoma	AbbVie	November 27 2017	Phase 1
NCT02520778	Active not recruiting	Drug: Navitoclax\|Drug: Osimertinib	Advanced Lung Non-Squamous Non-Small Cell Carcinoma\|Metastatic Lung Non-Squamous Non-Small Cell Carcinoma\|Stage III Lung Non-Small Cell Cancer AJCC v7\|Stage IIIA Lung Non-Small Cell Cancer AJCC v7\|Stage IIIB Lung Non-Small Cell Cancer AJCC v7\|Stage IV Lung Non-Small Cell Cancer AJCC v7	National Cancer Institute (NCI)	March 31 2016	Phase 1
NCT02591095	Completed	Drug: ABT-263	Platinum-resistant or Refractory Ovarian Cancer	Centre Francois Baclesse\|ARCAGY/ GINECO GROUP\|French Cancer Research Hospital Program	January 2016	Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?
回答：
S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.
问题 2：
Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?
回答：
According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

选择性强的Bcl-2抑制剂

ABT-199 (GDC-0199) : Bcl-2-selective, K_i<0.01 nM.
用于临床的Bcl-2抑制剂

Obatoclax Mesylate (GX15-070) : Phase II for leukemia, lymphoma, myelofibrosis, and mastocytosis.
最新的Bcl-2家族激活剂

BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.
经典的Bcl-2抑制剂

ABT-737 : BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

研究领域

产品类型

定制您的化合物库

Navitoclax (ABT-263)

客户使用Selleck生产的Navitoclax (ABT-263)发表文献201篇：

产品安全说明书

Bcl-2抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Navitoclax (ABT-263) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-09-01)

技术支持

常见问题及建议解决方法

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

相关Bcl-2产品